PHARVARIS NV

Pharvaris NV insiders buy at discount, sell at premium and liquidate options—showing bullish confidence in its B₂‑receptor pain drugs and upcoming regulatory approvals.

Pharvaris insider sale sparks debate: learn how a routine 109‑share sell reflects confidence amid strong rally, regulatory milestones, and extended‑release innovation.

Pharvaris insider sales show routine liquidity moves, not a sign of confidence, as the stock keeps rising on solid earnings and a strong B2‑receptor pipeline.

Pharvaris insider trades show confidence in its oral B2 antagonist pipeline for fibrosis, with Lu Peng buying low, selling high, and signaling a steady upside.

Pharvaris NV insider sales show routine, Rule 10b‑5‑1‑guided moves—no bearish signal, just confident execs backing a promising B2‑receptor pain drug amid rising investor interest.

Pharvaris insider sales signal a strategic re‑balance: Nijdam Anna cuts stake while keeping 49,488 shares, hinting at liquidity optimisation amid clinical‑stage growth.

Pharvaris NV insider sale: Anna Nijdam sold 1,164 shares at $28.25 on Apr 1, 2026. The modest move signals liquidity, not a bearish stance, amid key Phase‑3 and NDA milestones that could drive future upside.

Pharvaris NV insider Abele Stefan Andreas now holds 49,216 shares after a 3/A filing, signaling executive confidence amid Phase 3 clinical progress and value‑based care trends.

Pharvaris NV insider holdings reveal confidence in its oral B2 antagonist launch, payer talks, and phased option vesting—highlighting low agency risk and upside potential for investors.